Replenish Revenue by Low‐Cost Medicines, an Institution‐Specific Action to Improve Access to High‐Cost Medicines Used for Chronic Illness in Ethiopia: Narrative Review

Medicines used for chronic diseases are neither available nor affordable. The RRLCM model has potential to improve affordability, pending empirical validation. Therefore, it is important to reform national drug policy in light of pricing and markup regulation system. Researchers, who are willing to work in the similar area should evaluate the applicability of RRLCM model in different set-ups.